(Q34236623)

31 July 2017

1 reference

title

Angiotensin-converting enzyme inhibitors. (English)

1 reference

31 July 2017

Menard J

1

1 reference

31 July 2017

Patchett AA

series ordinal

2

1 reference

31 July 2017

publication date

1 January 2001

1 reference

Advances in Protein Chemistry

31 July 2017

published in

1 reference

31 July 2017

volume

56

1 reference

31 July 2017

page(s)

13-75

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

31 July 2017

1 reference

7 January 2021

Enzymes of the Renin-Angiotensin System and their Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Evidence-based medicine. A new approach to teaching the practice of medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Uncertainty in clinical practice: implications for quality and costs of health care.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Getting research findings into practice. When to act on the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

An assessment of clinically useful measures of the consequences of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Prostaglandins, prostacyclin, and thromboxanes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Influence of graded arterial pressure decrement on renal clearance of creatinine, p-aminohippurate and sodium

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The Regulation of Extracellular Fluid Volume

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Mechanisms regulating renin release

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Mechanism of renin release following furosemide diuresis in rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Re-evaluation of the role of hypovolemia on the release of renin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Renin secretion in renal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Hypertension in chronic renal failure. An abnormal relation between sodium and the renin-angiotensin system.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The Vicious Circle in Acute Malignant Hypertension of Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

THE EFFECTS OF INTRAVENOUS INFUSIONS OF VALINE-5 ANGIOTENSIN II AND OTHER PRESSOR AGENTS ON URINARY ELECTROLYTES AND CORTICOSTEROIDS, INCLUDING ALDOSTERONE.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

PLASMA RENIN CONCENTRATION IN HUMAN HYPERTENSION. 1. RELATIONSHIP BETWEEN RENIN, SODIUM, AND POTASSIUM

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Abnormal renal sodium handling in essential hypertension. Relation to failure of renal and adrenal modulation of responses to angiotensin II

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The preparation and function of the hypertensin-converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Renin- and non-renin–mediated antihypertensive actions of converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Possible role of kinins in circulatory homeostasis. State of the art review

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The antihypertensive effect of captopril. Evidence for an influence of kinins

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The release and fate of vaso-active hormones in the circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Abnormal renal haemodynamics and renin suppression in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin-forming enzyme in brain tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin-Converting Enzyme and the Regulation of Vasoactive Peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The purification of hypertensin I.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The amino acid composition of hypertensin II and its biochemical relationship to hypertensin I.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Molecular biology of the angiotensin I converting enzyme: I. Biochemistry and structure of the gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

18 Peptidyl dipeptidase A: Angiotensin I-converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

N-domain selectivity of angiotensin I-converting enzyme as assessed by structure-function studies of its highly selective substrate, N-acetyl-seryl-aspartyl-lysyl-proline

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The broad substrate specificity of human angiotensin I converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Structural basis of the action of thermolysin and related zinc peptidases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Identification of N-linked glycosylation sites in human testis angiotensin-converting enzyme and expression of an active deglycosylated form

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

History of the development of inhibitors of angiotensin I conversion

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

History of the design of captopril and related inhibitors of angiotensin converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Potentiation of bradykinin and eledoisin by BPF (bradykinin potentiating factor) from Bothrops jararaca venom

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The detection and estimation of bradykinin in the circulating blood

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Some properties of angiotensin converting enzyme in the lung in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Conversion of Angiotensin I to Angiotensin II by Cell-free Extracts of Dog Lung

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Structure of bradykinin-potentiating peptide containing tryptophan from the venom ofAgkistrodon halys blomhoffii

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Bradykinin-potentiating peptides from the venom of Agkistrodon halys blomhoffi. Isolation of five bradykinin potentiators and the amino acid sequences of two of them, potentiators B and C.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Bradykinin potentiating peptide PCA-Lys-Trp-Ala-Pro. An inhibitor of the pulmonary inactivation of bradykinin and conversion of angiotensin I to II

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a or SQ 20,881) which inhibits converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Estimating renin participation in hypertension: Superiority of converting enzyme inhibitor over saralasin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The effect of the converting enzyme inhibitor SQ 20.881 on kinins, renin-angiotensin-aldosterone and catecholamines in relation to blood pressure in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Design of new antihypertensive drugs: Potent and specific inhibitors of angiotensin-converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin-converting enzyme inhibitors: Medicinal chemistry and biological actions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

From peptides to peptidases: a chronicle of drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Captopril: pharmacology, metabolism and disposition

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

A specific orally active inhibitor of angiotensin-converting enzyme in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Captopril: five years on.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin-converting enzyme inhibitors in the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The chemistry of enalapril

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Studies on inhibitory effect of phosphoramidon and its analogs on thermolysin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

CAPTOPRIL IN THE TREATMENT OF CLINICAL HYPERTENSION AND CARDIAC FAILURE

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

A new class of angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Recent developments in the design of angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Three new long-acting converting-enzyme inhibitors: Relationship between plasma converting-enzyme activity and response to angiotensin I

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Enalapril maleate and a lysine analogue (MK-521): disposition in man

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Lisinopril dose-response relationship in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

(Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme (ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L -proline a novel orally active inhibitor of ACE.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

(Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme. 2. Terminal amino acid analogues of (S)-1-[6-amino-2 [[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Ceranapril (SQ 29,852), an Orally Active Inhibitor of Angiotensin Converting Enzyme (ACE)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Blood Pressure Lowering and Renal Hemodynamic Effects of Fosinopril in Conscious Animal Models

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Disposition of fosinopril sodium in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Fosinopril: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Newer ACE inhibitors. A look at the future

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Clinical pharmacokinetics of the newer ACE inhibitors. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Overview of quinapril, a new ACE inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Quinapril. A review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Clinical pharmacokinetics of ramipril

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Trandolapril: a clinical profile

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Greene LL, Ferreira SH: Potential screening test for detection of overactivity of renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Hypertension of renal origin: evidence for two different mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Maintenance of blood pressure by the renin–angiotensin system in normal man

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Contrasting exchangeable sodium in rats with different types of Goldblatt hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Converting enzyme inhibitor and saralasin infusion in rats. Evidence for an additional vasodepressor property of converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Increased plasma renin activity induced in rats by physostigmine and effects of alpha- and beta-receptors blocking drugs thereon

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Synthesis and renin inhibitory properties of a new soluble pepstatin derivative

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Cardiovascular reflexes during long-term converting enzyme inhibition and sodium depletion. The response to tilt in hypertensive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin I-converting enzyme genotype influences arterial response to injury in normotensive rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Regulation of endothelial nitric oxide synthase mRNA, protein, and activity during cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Concentration-effect analysis of antihypertensive drug responses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Kinetic-dynamic relations and individual responses to enalapril

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Predictability of antihypertensive responsiveness and alpha-adrenoceptor antagonism during prazosin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Additive effects of losartan and enalapril on blood pressure and plasma active renin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Circulating and tissue angiotensin systems

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Determinants of angiotensin II generation during converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Government viewpoint of clinical trials of cardiovascular drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Some problems with antihypertensive drug studies in the context of the new guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Lisinopril: dose-peak effect relationship in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Crossover design to test antihypertensive drugs with self-recorded blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Crossover design for the dose determination of an angiotensin converting enzyme inhibitor in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Cardiovascular effects, pharmacokinetics, and converting enzyme inhibition of enalapril after morning versus evening administration

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The two-period cross-over clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Double-blind crossover versus parallel groups in hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Measurement of converting enzyme activity by antibody-trapping of generated angiotensin II. Comparison with two other methods

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin II-forming pathways in normal and failing human hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Chymase-dependent angiotensin II formation in human vascular tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Alteration of the Course of Hypertension in the Spontaneously Hypertensive Rat

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Captopril and hypertension development in the SHR.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

MK 421 and prevention of genetic hypertension development in young spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Cardiac hypertrophy in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin converting enzyme inhibition of renin system activity induces reversal of hypertensive target organ changes. Do these effects predict a reduction in long-term morbidity?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Tissue angiotensin system in cardiovascular medicine. A paradigm shift?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe heritable hyperlipidemic rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Concentration of renin in renal venous blood in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Plasma Renin in Chronic Experimental Heart Failure and during Renal Sodium "Escape" from Mineralocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The renin-angiotensin-aldosterone system in congestive failure in conscious dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin converting enzyme inhibition in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Sustained Effectiveness of Converting-Enzyme Inhibition in Patients with Severe Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of vasodilators on survival in chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

ACE inhibitors in acute myocardial infarction: patient selection and timing

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Essential hypertension: renin and aldosterone, heart attack and stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Plasma renin activity and ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Renin-angiotensin system inhibition in conscious sodium-depleted dogs. Effects on systemic and coronary hemodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The effect of angiotensin converting enzyme inhibition on coronary blood flow and hemodynamics in patients without coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Diurnal variation of pulmonary artery pressure in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Hemodynamic shear stress and its role in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Reversing endothelial dysfunction with ACE inhibitors. A new trend

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter Euro

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transl

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

D Allele of the Angiotensin I–Converting Enzyme Is a Major Risk Factor for Restenosis After Coronary Stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Plasma Activity and Insertion/Deletion Polymorphism of Angiotensin I–Converting Enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

A rapid ultrastructural embedding procedure for renal biopsy tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effects of antihypertensive treatment in one-clip, two kidney hypertension in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Comparison of the hormonal and renal effects of captopril in severe essential and renovascular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Captopril-Induced Functional Renal Insufficiency in Patients with Bilateral Renal-Artery Stenoses or Renal-Artery Stenosis in a Solitary Kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Blood pressure and end-stage renal disease in men

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function. A retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Renoprotective therapy: titration against urinary protein excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Normotension and hypertension: the mysterious viability of the false.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Labile hypertension: a faulty concept? The Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Continuous versus intermittent angiotensin converting enzyme inhibition in renal hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Management of raised blood pressure in New Zealand: a discussion document

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Blood pressure management: individualized treatment based on absolute risk and the potential for benefit

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The absolute risk as a guide to influence the treatment decision-making process in mild hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Blood pressure, stroke, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Selective alpha 1-adrenergic blockade, lipids, and coronary heart disease risk. Considerations in the treatment of mild hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Suppositions and speculations--their possible effects on treatment decisions in the management of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Treatment of mild to moderate hypertension with or without the converting enzyme inhibitor enalapril. Results of a six-month double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Post marketing surveillance of captopril (for hypertension): a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The cost-effectiveness of the switch towards more expensive antihypertensive drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The National Consensus Conference--not always what it seems.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Are surrogate markers adequate to assess cardiovascular disease drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The progression from hypertension to congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Interpreting, integrating, and individualizing evidence about the prevention of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Are prescription drug prices high?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Inhibitors of neprilysin: design, pharmacological and clinical applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Inhibitors of angiotensin-converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

The clinical pharmacology of lisinopril

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Prediction of the antihypertensive response to enalapril

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Reproducibility of non-invasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

Mild hypertension: the mysterious viability of a faulty concept.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956002-7

7 January 2021

10.1016/S0065-3233(01)56002-7

Identifiers

DOI

1 reference

31 July 2017

1 reference